

**SUMMARY:** The Advisory Committee on Bankruptcy Rules will hold an in-person meeting in hybrid format with remote attendance options on September 23, 2026 in Washington, DC. The meeting is open to the public for observation but not participation. Please see the Supplementary Information section in this notice for instructions on observing the meeting.

**DATES:** September 23, 2026 (meeting date) and September 16, 2026 (registration deadline for in-person observation).

**ADDRESSES:** An agenda and supporting materials will be posted at least 7 days in advance of the meeting at: <https://www.uscourts.gov/forms-rules/records-rules-committees/agenda-books>.

**FOR FURTHER INFORMATION CONTACT:** Carolyn A. Dubay, Chief Counsel, Rules Committee Staff, Administrative Office of the U.S. Courts, Thurgood Marshall Federal Judiciary Building, One Columbus Circle NE, Suite 7-300, Washington, DC 20544, Phone (202) 502-1820, [RulesCommittee\\_Secretary@ao.uscourts.gov](mailto:RulesCommittee_Secretary@ao.uscourts.gov).

**SUPPLEMENTARY INFORMATION:** To observe the meeting in person, individuals must contact the office listed above by 5 p.m. (eastern time) on September 16, 2026. After this deadline, only remote observation is permitted. Remote registration is available until the meeting date, provided it is completed before the projected end time.

(Authority: 28 U.S.C. 2073.)

Dated: June 11, 2026.

**Shelly L. Cox,**

*Management Analyst, Rules Committee Staff.*

[FR Doc. 2026-11983 Filed 6-12-26; 8:45 am]

**BILLING CODE 2210-55-P**

## JUDICIAL CONFERENCE OF THE UNITED STATES

### Advisory Committee on Civil Rules; Meeting of the Judicial Conference

**AGENCY:** Judicial Conference of the United States.

**ACTION:** Advisory Committee on Civil Rules; notice of open meeting.

**SUMMARY:** The Advisory Committee on Civil Rules will hold an in-person meeting in hybrid format with remote attendance options on October 21, 2026 in Washington, DC. The meeting is open to the public for observation but not participation. Please see the Supplementary Information section in this notice for instructions on observing the meeting.

**DATES:** October 21, 2026 (meeting date) and October 14, 2026 (registration deadline for in-person observation).

**ADDRESSES:** An agenda and supporting materials will be posted at least 7 days in advance of the meeting at: <https://www.uscourts.gov/forms-rules/records-rules-committees/agenda-books>.

**FOR FURTHER INFORMATION CONTACT:** Carolyn A. Dubay, Chief Counsel, Rules Committee Staff, Administrative Office of the U.S. Courts, Thurgood Marshall Federal Judiciary Building, One Columbus Circle NE, Suite 7-300, Washington, DC 20544, Phone (202) 502-1820, [RulesCommittee\\_Secretary@ao.uscourts.gov](mailto:RulesCommittee_Secretary@ao.uscourts.gov).

**SUPPLEMENTARY INFORMATION:** To observe the meeting in person, individuals must contact the office listed above by 5 p.m. (eastern time) on October 14, 2026. After this deadline, only remote observation is permitted. Remote registration is available until the meeting date, provided it is completed before the projected end time.

(Authority: 28 U.S.C. 2073.)

Dated: June 11, 2026.

**Shelly L. Cox,**

*Management Analyst, Rules Committee Staff.*

[FR Doc. 2026-11984 Filed 6-12-26; 8:45 am]

**BILLING CODE 2210-55-P**

## JUDICIAL CONFERENCE OF THE UNITED STATES

### Advisory Committee on Criminal Rules; Meeting of the Judicial Conference

**AGENCY:** Judicial Conference of the United States.

**ACTION:** Advisory Committee on Criminal Rules; notice of open meeting.

**SUMMARY:** The Advisory Committee on Criminal Rules will hold an in-person meeting in hybrid format with remote attendance options on October 14, 2026 in Boston, MA. The meeting is open to the public for observation but not participation. Please see the **SUPPLEMENTARY INFORMATION** section in this notice for instructions on observing the meeting.

**DATES:** October 14, 2026 (meeting date) and October 7, 2026 (registration deadline for in-person observation).

**ADDRESSES:** An agenda and supporting materials will be posted at least 7 days in advance of the meeting at: <https://www.uscourts.gov/forms-rules/records-rules-committees/agenda-books>.

**FOR FURTHER INFORMATION CONTACT:** Carolyn A. Dubay, Chief Counsel, Rules Committee Staff, Administrative Office

of the U.S. Courts, Thurgood Marshall Federal Judiciary Building, One Columbus Circle NE, Suite 7-300, Washington, DC 20544, Phone (202) 502-1820, [RulesCommittee\\_Secretary@ao.uscourts.gov](mailto:RulesCommittee_Secretary@ao.uscourts.gov).

**SUPPLEMENTARY INFORMATION:** To observe the meeting in person, individuals must contact the office listed above by 5 p.m. (eastern time) on October 7, 2026. After this deadline, only remote observation is permitted. Remote registration is available until the meeting date, provided it is completed before the projected end time.

(Authority: 28 U.S.C. 2073.)

Dated: June 11, 2026.

**Shelly L. Cox,**

*Management Analyst, Rules Committee Staff.*

[FR Doc. 2026-11981 Filed 6-12-26; 8:45 am]

**BILLING CODE 2210-55-P**

## JUDICIAL CONFERENCE OF THE UNITED STATES

### Advisory Committee on Appellate Rules; Meeting of the Judicial Conference

**AGENCY:** Judicial Conference of the United States.

**ACTION:** Advisory Committee on Appellate Rules; notice of open meeting.

**SUMMARY:** The Advisory Committee on Appellate Rules will hold an in-person meeting in hybrid format with remote attendance options on October 6, 2026 in Washington, DC. The meeting is open to the public for observation but not participation. Please see the **SUPPLEMENTARY INFORMATION** section in this notice for instructions on observing the meeting.

**DATES:** October 6, 2026 (meeting date) and September 29, 2026 (registration deadline for in-person observation).

**ADDRESSES:** An agenda and supporting materials will be posted at least 7 days in advance of the meeting at: <https://www.uscourts.gov/forms-rules/records-rules-committees/agenda-books>.

**FOR FURTHER INFORMATION CONTACT:** Carolyn A. Dubay, Chief Counsel, Rules Committee Staff, Administrative Office of the U.S. Courts, Thurgood Marshall Federal Judiciary Building, One Columbus Circle NE, Suite 7-300, Washington, DC 20544, Phone (202) 502-1820, [RulesCommittee\\_Secretary@ao.uscourts.gov](mailto:RulesCommittee_Secretary@ao.uscourts.gov).

**SUPPLEMENTARY INFORMATION:** To observe the meeting in person, individuals must contact the office listed above by 5 p.m. (eastern time) on September 29, 2026. After this deadline,

only remote observation is permitted. Remote registration is available until the meeting date, provided it is completed before the projected end time.

(Authority: 28 U.S.C. 2073.)

Dated: June 11, 2026.

Shelly L. Cox,

Management Analyst, Rules Committee Staff.

[FR Doc. 2026-11985 Filed 6-12-26; 8:45 am]

BILLING CODE 2210-55-P

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-1727]

#### Importer of Controlled Substances Application: Cerilliant Corporation

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Cerilliant Corporation has applied to be registered as an importer of basic class(es) of controlled

substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on, or objections to the issuance of the proposed registration on or before July 15, 2026. Such persons may also file a written request for a hearing on the application on or before July 15, 2026.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public

view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on May 8, 2026, Cerilliant Corporation, 811 Paloma Drive, Round Rock, Texas 78665-2402, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Controlled substance                                                                                         | Drug code | Schedule |
|--------------------------------------------------------------------------------------------------------------|-----------|----------|
| 3-Fluoro-N-methylcathinone (3-FMC) .....                                                                     | 1233      | I.       |
| Cathinone .....                                                                                              | 1235      | I.       |
| Methcathinone .....                                                                                          | 1237      | I.       |
| 4-Fluoro-N-methylcathinone (4-FMC) .....                                                                     | 1238      | I.       |
| Pentedrone ( $\alpha$ -methylaminovalerophenone) .....                                                       | 1246      | I.       |
| Mephedrone (4-Methyl-N-methylcathinone) .....                                                                | 1248      | I.       |
| 4-Methyl-N-ethylcathinone (4-MEC) .....                                                                      | 1249      | I.       |
| Naphyrone .....                                                                                              | 1258      | I.       |
| N-Ethylamphetamine .....                                                                                     | 1475      | I.       |
| N,N-Dimethylamphetamine .....                                                                                | 1480      | I.       |
| Fenethylamine .....                                                                                          | 1503      | I.       |
| Methaqualone .....                                                                                           | 2565      | I.       |
| JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) .....                                                    | 6250      | I.       |
| SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) .....                       | 7008      | I.       |
| 5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ..... | 7011      | I.       |
| AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .....        | 7012      | I.       |
| JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) .....                                                                | 7019      | I.       |
| AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .....                    | 7023      | I.       |
| THJ-2201 [(1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone] .....                              | 7024      | I.       |
| AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) .....      | 7031      | I.       |
| ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .....               | 7035      | I.       |
| APINACA and AKB48 (N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide) .....                                 | 7048      | I.       |
| JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) .....                                                    | 7081      | I.       |
| SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole) .....                                  | 7104      | I.       |
| JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .....                                         | 7118      | I.       |
| JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) .....                                                     | 7122      | I.       |
| UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .....                               | 7144      | I.       |
| JWH-073 (1-Butyl-3-(1-naphthoyl)indole) .....                                                                | 7173      | I.       |
| JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) .....                                             | 7200      | I.       |
| AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) .....                                                     | 7201      | I.       |
| JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) .....                                                     | 7203      | I.       |
| PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) .....                                                 | 7222      | I.       |
| 5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) .....                                    | 7225      | I.       |
| Alpha-ethyltryptamine .....                                                                                  | 7249      | I.       |
| Ibogaine .....                                                                                               | 7260      | I.       |
| CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol] .....                               | 7297      | I.       |
| CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol] .....                   | 7298      | I.       |
| Lysergic acid diethylamide .....                                                                             | 7315      | I.       |
| 2C-T-7 (2,5-Dimethoxy-4-(n)-propylthiophenethylamine .....                                                   | 7348      | I.       |
| Marihuana .....                                                                                              | 7360      | I.       |
| Parahexyl .....                                                                                              | 7374      | I.       |
| Mescaline .....                                                                                              | 7381      | I.       |
| 2C-T-2 (2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine ) .....                                               | 7385      | I.       |